Xeptiva Therapeutics
Pipeline / Xep01 · Dog · Oncologic pain

Xep01 · Oncologic pain in dogs

The same immuno­gen as Xep01, eval­u­ated against the neu­ro­genic inflam­ma­tion that sus­tains cancer pain in dogs.

ProgramXep01
SpeciesDog
IndicationOncologic pain
StagePOC clinical trial
The disease

Why it matters

Pain is one of the most common and least con­trolled con­se­quences of cancer in dogs, from bone tumors to soft-tissue tumors. It com­bines inflam­ma­tory and neu­ro­pathic com­po­nents, and in advanced disease it often limits quality of life before the tumor itself does. NSAIDs and opioids remain the stan­dard of care, with limits on long-term use.

Target and mechanism

What the vaccine does

The same immuno­gen as Xep01 for osteoarthri­tis pain, eval­u­ated here for pain asso­ci­ated with cancer. In cancer pain, as in osteoarthri­tis, NGF and Sub­stance P sen­si­tize nerve endings, and Sub­stance P acti­vates mast cells and sus­tains neu­ro­genic inflam­ma­tion around the tumor.

How the platform works →
Evidence

Efficacy

  • An effi­cacy trial in dogs with cancer pain is cur­rently under­way.
Partnering

Interested in this program?

Pro­to­cols, study reports and the reg­u­la­tory package are avail­able to qual­i­fied part­ners under con­fi­den­tial­ity.

Request data room accessBack to the pipeline